Organon & Co. (OGN) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $13.31, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international (outside United States) (74.0%); Analyst target reached - limited upside remaining.
Organon & Co. is a global healthcare company with 70+ products in women's health (including Nexplanon contraceptive and Follistim fertility) and general medicines (biosimilars and established brands) across 140+ countries. The company generated approximately $4.6 billion of... Read more
Hold if already holding. Not a fresh buy at $13.31, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international (outside United States) (74.0%); Analyst target reached - limited upside remaining. Chart setup: Death cross but MACD improving, RSI 78. Downgraded from BUY WAIT — price $13.31 has reached target $13.12. No upside to wait for. Score 5.0/10, high confidence.
Passes 4/7 gates (positive momentum, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 0d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicinternational (outside United States)74%10-K Item 1A: 'in 2025, we generated $4.6 billion in revenues outside the United States, representing approximately 74% of our total revenues'
- MEDIUMSupplierSamsung Bioepis, Henlius and Biothera biosimilar suppliers10-K Item 1A: 'We rely on our commercialization agreements with Samsung Bioepis, Henlius and Biothera for the successful development and manufacture of our biosimilars products'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Revenue shrinking — -5.3% YoY. Growth thesis broken unless recovery story develops.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $13.31, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: international (outside United States) (74.0%); Analyst target reached - limited upside remaining. Chart setup: Death cross but MACD improving, RSI 78. Downgraded from BUY WAIT — price $13.31 has reached target $13.12. No upside to wait for. Target $13.12 (-1.4%), stop $9.91 (−34.3%), A.R:R -1.9:1. Score 5.0/10, high confidence.
Take-profit target: $13.12 (+23.1% upside). Target $13.12 (-1.4%), stop $9.91 (−34.3%), A.R:R -1.9:1. Stop-loss: $9.91.
Concentration risk — Geographic: international (outside United States) (74.0%); Analyst target reached - limited upside remaining; Near 52-week high (0.5% away).
Organon & Co. trades at a P/E of 18.5 (forward 3.6). TrendMatrix value score: 7.9/10. Verdict: Hold.
16 analysts cover OGN with a consensus score of 2.4/5. Average price target: $11.
What does Organon & Co. do?Organon & Co. is a global healthcare company with 70+ products in women's health (including Nexplanon contraceptive and...
Organon & Co. is a global healthcare company with 70+ products in women's health (including Nexplanon contraceptive and Follistim fertility) and general medicines (biosimilars and established brands) across 140+ countries. The company generated approximately $4.6 billion of revenues outside the United States in 2025, representing 74% of total revenues, sold through wholesalers, hospitals, and managed care providers.